已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis

医学 内科学 肿瘤科 结直肠癌 危险系数 荟萃分析 子群分析 阶段(地层学) 化疗 循环肿瘤DNA 佐剂 微小残留病 癌症 生物标志物 置信区间 化学 白血病 古生物学 生物 生物化学
作者
Anusha Chidharla,Eliot Rapoport,Kriti Agarwal,Samragnyi Madala,Brenda Linares,Weijing Sun,Sakti Chakrabarti,Anup Kasi
出处
期刊:International Journal of Molecular Sciences [Multidisciplinary Digital Publishing Institute]
卷期号:24 (12): 10230-10230 被引量:20
标识
DOI:10.3390/ijms241210230
摘要

Emerging data have suggested that circulating tumor DNA (ctDNA) can be a reliable biomarker for minimal residual disease (MRD) in CRC patients. Recent studies have shown that the ability to detect MRD using ctDNA assay after curative-intent surgery will change how to assess the recurrence risk and patient selection for adjuvant chemotherapy. We performed a meta-analysis of post-operative ctDNA in stage I–IV (oligometastatic) CRC patients after curative-intent resection. We included 23 studies representing 3568 patients with evaluable ctDNA in CRC patient post-curative-intent surgery. Data were extracted from each study to perform a meta-analysis using RevMan 5.4. software. Subsequent subgroup analysis was performed for stages I–III and oligometastatic stage IV CRC patients. Results showed that the pooled hazard ratio (HR) for recurrence-free survival (RFS) in post-surgical ctDNA-positive versus -negative patients in all stages was 7.27 (95% CI 5.49–9.62), p < 0.00001. Subgroup analysis revealed pooled HRs of 8.14 (95% CI 5.60–11.82) and 4.83 (95% CI 3.64–6.39) for stages I–III and IV CRC, respectively. The pooled HR for RFS in post-adjuvant chemotherapy ctDNA-positive versus -negative patients in all stages was 10.59 (95% CI 5.59–20.06), p < 0.00001. Circulating tumor DNA (ctDNA) analysis has revolutionized non-invasive cancer diagnostics and monitoring, with two primary forms of analysis emerging: tumor-informed techniques and tumor-agnostic or tumor-naive techniques. Tumor-informed methods involve the initial identification of somatic mutations in tumor tissue, followed by the targeted sequencing of plasma DNA using a personalized assay. In contrast, the tumor-agnostic approach performs ctDNA analysis without prior knowledge of the patient’s tumor tissue molecular profile. This review highlights the distinctive features and implications of each approach. Tumor-informed techniques enable the precise monitoring of known tumor-specific mutations, leveraging the sensitivity and specificity of ctDNA detection. Conversely, the tumor-agnostic approach allows for a broader genetic and epigenetic analysis, potentially revealing novel alterations and enhancing our understanding of tumor heterogeneity. Both approaches have significant implications for personalized medicine and improved patient outcomes in the field of oncology. The subgroup analysis based on the ctDNA method showed pooled HRs of 8.66 (95% CI 6.38–11.75) and 3.76 (95% CI 2.58–5.48) for tumor-informed and tumor-agnostic, respectively. Our analysis emphasizes that post-operative ctDNA is a strong prognostic marker of RFS. Based on our results, ctDNA can be a significant and independent predictor of RFS. This real-time assessment of treatment benefits using ctDNA can be used as a surrogate endpoint for the development of novel drugs in the adjuvant setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
海派Hi完成签到 ,获得积分10
2秒前
非洲大象给非洲大象的求助进行了留言
2秒前
皮皮完成签到 ,获得积分10
6秒前
鲁路修完成签到,获得积分10
7秒前
喜悦的小土豆完成签到 ,获得积分10
8秒前
8秒前
读书的时候完成签到,获得积分10
10秒前
高兴1江完成签到,获得积分10
10秒前
轻松的惜芹应助CC采纳,获得10
13秒前
ofafafa完成签到 ,获得积分10
19秒前
brick2024完成签到,获得积分10
20秒前
21秒前
劳健龙完成签到 ,获得积分10
21秒前
侃侃完成签到,获得积分10
23秒前
阿鑫完成签到 ,获得积分10
25秒前
流年发布了新的文献求助10
26秒前
mumufan完成签到,获得积分10
26秒前
28秒前
xiaa0618完成签到 ,获得积分10
32秒前
35秒前
隐形曼青应助白云垛采纳,获得10
36秒前
谦让的雅青完成签到 ,获得积分10
36秒前
LJL完成签到 ,获得积分10
39秒前
钱仙人完成签到,获得积分10
40秒前
幸符完成签到 ,获得积分10
41秒前
科研达人发布了新的文献求助10
42秒前
谨慎秋珊完成签到 ,获得积分10
42秒前
45秒前
yanghong发布了新的文献求助10
46秒前
迟暮完成签到 ,获得积分10
47秒前
SciGPT应助科研喵采纳,获得10
49秒前
非洲大象完成签到,获得积分10
49秒前
桃桃发布了新的文献求助10
50秒前
m1nt完成签到,获得积分0
55秒前
领导范儿应助科研通管家采纳,获得10
55秒前
大模型应助科研通管家采纳,获得10
55秒前
Rondab应助科研通管家采纳,获得10
55秒前
Rondab应助科研通管家采纳,获得10
55秒前
yanghong完成签到,获得积分10
56秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989972
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256042
捐赠科研通 3270884
什么是DOI,文献DOI怎么找? 1805093
邀请新用户注册赠送积分活动 882256
科研通“疑难数据库(出版商)”最低求助积分说明 809216